Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

Multiple Sclerosis Clinical Trial

— SONIC  

Official title:

A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00629642
• Other study ID #: 905-EC-005
• Secondary ID: 2006-005523-42
• Status: Completed
• Phase: Phase 4
• First received: February 26, 2008
• Last updated: August 31, 2017
• Start date: March 14, 2008
• Est. completion date: January 28, 2011

Study information

• Verified date: August 2017
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis

Description:

A clinical study to compare the efficacy and safety of solifenacin succinate in patients with neurogenic detrusor overactivity. In this randomized, double blind, double dummy study solifenacin will be compared to placebo and an active comparator, oxybutynin hydrochloride. Patients will be randomized to one of four treatment arms; solifenacin 10mg, solifenacin 5mg, placebo or oxybutynin 15mg. Patients will be assessed over a four week treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 249
• Est. completion date: January 28, 2011
• Est. primary completion date: January 28, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Written informed consent has been obtained

• Subjects with neurogenic detrusor overactivity due to:

• Multiple sclerosis(MS)(EDSS=8) or

• Spinal cord injury(SCI)(partial or complete lesions)

• MS or SCI symptoms should be stable for >= 6 months

• Neurogenic detrusor overactivity symptoms should be stable for >= 6 months

• Subject is willing and able to perform clean, intermittent, catheterization, if required

• Subject is willing and able to take study medication in compliance with the protocol

Exclusion Criteria:

• Subjects with neurogenic detrusor overactivity due to Parkinson's or cerebrovascular disease

• Subjects with Sjögren's Syndrome or any similar symptoms

• Subjects with evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs

• Subjects with stress incontinence or mixed incontinence where stress is the predominant factor as determined by the investigator

• Subjects with evidence of pressure sores >= grade 2

• Subjects with a history of bladder sphincterotomy

• Subjects with known history of vesico-ureteral reflux without upper urinary tract infection

• Any clinically significant condition, which in the opinion of the investigator makes the subject unsuitable for the study or includes a history of acute urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony), severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis), myasthenia gravis, narrow angle glaucoma or shallow anterior chamber

• Subjects undergoing hemodialysis

• Subjects with severe hepatic impairment

• Concurrent use of drugs intended to treat symptoms of overactive bladder

• Use of antidepressants or muscle relaxants which have not been administered at a constant dose for >= 3 months

• Use of non-drug treatment intended to treat overactive bladder symptoms including electrostimulation therapy, botulinum toxin and vanilloids therapy in the six months prior to the commencement of the study

• Use of permanent, indwelling catheters

• Known or suspected hypersensitivity to solifenacin succinate, oxybutynin hydrochloride, other anti cholinergics or lactose

• Concomitant use of a strong CYP3A4 inhibitor, e.g. ketoconazole

• Pregnant women, women who intend to become pregnant during the study, women of childbearing potential who are sexually active and practicing an unreliable method of birth control or women who will be lactating during the study. Reliable contraceptive methods are intra-uterine devices, contraceptive pills of combination type, hormonal implants and injectable contraceptives

• Participation in any clinical study within 30 days of randomization, or the limit set by national law, whichever is longer

• Employees of the Astellas Group, third parties associated with the study, or the study site

• Subjects with maximum bladder capacity >= 400ml at visit 2

Related Conditions & MeSH terms

• Multiple Sclerosis
• Neurogenic Bladder
• Sclerosis
• Spinal Cord Diseases
• Urinary Bladder, Neurogenic

Intervention

Drug:
• Solifenacin Succinate
Oral, 10mg
• Solifenacin Succinate
Oral, 5mg
• Oxybutynin Hydrochloride
Oral, 15mg
• Placebo
Oral

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Countries where clinical trial is conducted

Australia,  Belgium,  Czechia,  France,  Germany,  Hungary,  Italy,  Netherlands,  Russian Federation,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in maximum cystometric capacity		4 Weeks
Secondary	Change from baseline in bladder volume at first involuntary contraction		4 Weeks
Secondary	Change from baseline in pressure at first leak		4 Weeks
Secondary	Change from baseline in volume at first leak		4 Weeks
Secondary	Change from baseline in maximum detrusor pressure		4 Weeks
Secondary	Change from baseline in micturition or catheterization frequency		4 Weeks
Secondary	Change from baseline in incontinence episodes		4 Weeks
Secondary	Incidence and severity of adverse events		4 Weeks

External Links

•   Link to results on the Astellas Clinical Study Results website.